In order to be able to undergo the NovaVision NeuroEyeCoach therapy program, you will need to be able to fulfill the following minimum requirements:
Physical Or Medical
- Able to sit upright and concentrate without distraction for training sessions lasting approximately 15-20 minutes, two-six times a day for a maximum of two hours and for a minimum of three times a week.
- Able to operate comfortably the left and right buttons of a mouse or the left and right direction arrows on a computer keyboard.
- Able to demonstrate that you can see letters shown on the computer monitor by passing the NeuroEyeCoach simple online font-size test.
- Able to understand and follow written or audio instructions.
- Internet connection
- PC (desktop or laptop) with Windows XP Service Pack 3, Windows Vista, Windows 7 or Windows 8/8.1. NovaVision NeuroEyeCoach is not compatible with Apple OS, however it can be used with an Apple computer if Windows or a program such as Parallels (www.parallels.com) is installed.
- Screen size of 15” (diagonal) or greater is recommended, and NovaVision NeuroEyeCoach should not be run on a screen size below 13” (diagonal). Minimum screen resolution is 1024(W) x 768(H) and NovaVision NeuroEyeCoach will not operate below this minimum resolution.
- Some familiarity with computer operation and internet browsing. NovaVision NeuroEyeCoach requires an initial download and run of an Installation program from the NovaVision website portal. Your progress reports are also downloaded from the same portal.
Please note that, prior to completing the online registration questionnaire, the NovaVision portal will run a check on the technical attributes of the computer equipment being used to access the portal and will inform you if the technical requirements are not met.
If you are uncertain of the technical requirements or have questions, please contact NovaVision Support.
Contraindications, Warnings, And Precautions
Patients with the following medical or physical conditions must not undergo NovaVision NeuroEyeCoach therapy:
- History of seizure disorders, especially those of a photosensitive nature. In patients with uncontrolled photosensitive seizure disorders, NovaVision NeuroEyeCoach may have adverse effects including, but not limited to, seizures.
- Severe cognitive defects, particularly due to the requirement to be able concentrate for training sessions lasting approximately 15-20 minutes, two-six times a day for a maximum of two hours and for a minimum of three times a week.
- Patients with active acute inflammatory diseases of the eyes or central nervous system should not initiate NeuroEyeCoach until the acute phase has subsided.
- NovaVision NeuroEyeCoach will not be effective for patients without any residual vision whatsoever (i.e., total cortical blindness).
- NeuroEyeCoach requires patients to be seated for extended periods of time. If the patient has been previously diagnosed with deep vein thrombosis (DVT) or has been identified by their physician as having an increased risk of experiencing DVT, the patient should first consult with their physician before initiating NeuroEyeCoach.
The following conditions are not treatable by NeuroEyeCoach, may impact the ability of a patient to carry out NeuroEyeCoach, and/or may reduce its effectiveness:
- Uncorrected vision defects such as myopia, hyperopia, astigmatism, presbyopia or tropia (strabismus).
- Progressive disorders such as glaucoma, multiple sclerosis, diabetic retinopathy or macular degeneration.
- Although there are no age limits for the therapy, NeuroEyeCoach is not recommended for children, due to the requirement to be able to concentrate for training sessions lasting approximately 15-20 minutes, two-six times a day for a maximum of two hours and for a minimum of three times a week.
In common with all activities requiring extended use of a computer screen, NovaVision NeuroEyeCoach may cause light headaches or fatigue if performed too intensively or without sufficient relaxation periods (breaks). If this occurs, patients should take more frequent breaks during the session. If this persists, patients should temporarily discontinue the therapy until symptoms subside.